Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Aptamers: Promising Tools for Cancer Diagnosis and Therapy.

Cerchia L.

Cancers (Basel). 2018 May 3;10(5). pii: E132. doi: 10.3390/cancers10050132.

2.

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB.

Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E.

Oncotarget. 2018 Apr 13;9(28):19929-19944. doi: 10.18632/oncotarget.24961. eCollection 2018 Apr 13.

3.

Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.

Monaco M, Palma G, Vitiello M, Capiluongo A, D'Andrea B, Vuttariello E, Luciano A, Cerchia L, Chiappetta G, Arra C, Fusco A, Fedele M.

Cancers (Basel). 2018 Mar 27;10(4). pii: E92. doi: 10.3390/cancers10040092.

4.

Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.

Camorani S, Crescenzi E, Fedele M, Cerchia L.

Biochim Biophys Acta. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21. Review.

PMID:
29574128
5.

The POZ/BTB and AT-Hook Containing Zinc Finger 1 (PATZ1) Transcription Regulator: Physiological Functions and Disease Involvement.

Fedele M, Crescenzi E, Cerchia L.

Int J Mol Sci. 2017 Nov 24;18(12). pii: E2524. doi: 10.3390/ijms18122524. Review.

6.

The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.

Fedele M, Cerchia L, Chiappetta G.

Cancers (Basel). 2017 Sep 30;9(10). pii: E134. doi: 10.3390/cancers9100134. Review.

7.

PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.

Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, Arra C, Crescenzi E, Cerchia L, De Caro MLDB, Fedele M.

Oncotarget. 2017 Jul 25;8(35):59282-59300. doi: 10.18632/oncotarget.19546. eCollection 2017 Aug 29.

8.

Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.

Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A.

Theranostics. 2017 Aug 22;7(14):3595-3607. doi: 10.7150/thno.18974. eCollection 2017.

9.

Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.

Monaco I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A, Niclou S, Arra C, Chiariello M, Cerchia L, Comes Franchini M.

J Med Chem. 2017 May 25;60(10):4510-4516. doi: 10.1021/acs.jmedchem.7b00527. Epub 2017 May 10.

PMID:
28471660
10.

Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L.

Sci Rep. 2017 Apr 20;7:46659. doi: 10.1038/srep46659.

11.

PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.

Franco R, Scognamiglio G, Valentino E, Vitiello M, Luciano A, Palma G, Arra C, La Mantia E, Panico L, Tenneriello V, Pinto A, Frigeri F, Capobianco G, Botti G, Cerchia L, De Chiara A, Fedele M.

Oncotarget. 2016 Sep 13;7(37):59158-59172. doi: 10.18632/oncotarget.10993.

12.

PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells.

Vitiello M, Valentino T, De Menna M, Crescenzi E, Francesca P, Rea D, Arra C, Fusco A, De Vita G, Cerchia L, Fedele M.

Sci Rep. 2016 Apr 29;6:25268. doi: 10.1038/srep25268.

13.

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ieranò C, Cerchia L, Lucarelli E, Scala S, Zannetti A.

Cancer Lett. 2016 Jan 1;370(1):100-7. doi: 10.1016/j.canlet.2015.10.018. Epub 2015 Oct 27.

PMID:
26517945
14.

Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.

Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.

Oncotarget. 2015 Nov 10;6(35):37570-87. doi: 10.18632/oncotarget.6066.

15.

Oligonucleotide aptamers for glioma targeting: an update.

Camorani S, Cerchia L.

Cent Nerv Syst Agents Med Chem. 2015;15(2):126-37.

PMID:
25924917
16.

Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.

Camorani S, Esposito CL, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L.

Mol Ther. 2014 Apr;22(4):828-41. doi: 10.1038/mt.2013.300. Epub 2014 Jan 2.

17.

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2014 Jun;22(6):1151-1163. doi: 10.1038/mt.2014.5. Epub 2014 Jan 20.

18.

The isolectin IB4 binds RET receptor tyrosine kinase in microglia.

Boscia F, Esposito CL, Casamassa A, de Franciscis V, Annunziato L, Cerchia L.

J Neurochem. 2013 Aug;126(4):428-36. doi: 10.1111/jnc.12209. Epub 2013 Mar 17.

19.

Signal transduction alterations in glioma: implications for diagnosis and therapy.

Cerchia L, Martinez Montero JC, Monfared P.

J Signal Transduct. 2012;2012:704247. doi: 10.1155/2012/704247. Epub 2012 Dec 9. No abstract available.

20.

Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay.

Bettazzi F, Hamid-Asl E, Esposito CL, Quintavalle C, Formisano N, Laschi S, Catuogno S, Iaboni M, Marrazza G, Mascini M, Cerchia L, De Franciscis V, Condorelli G, Palchetti I.

Anal Bioanal Chem. 2013 Jan;405(2-3):1025-34. doi: 10.1007/s00216-012-6476-7. Epub 2012 Oct 26.

PMID:
23099529
21.

Targeting Axl with an high-affinity inhibitory aptamer.

Cerchia L, Esposito CL, Camorani S, Rienzo A, Stasio L, Insabato L, Affuso A, de Franciscis V.

Mol Ther. 2012 Dec;20(12):2291-303. doi: 10.1038/mt.2012.163. Epub 2012 Aug 21.

22.

Nucleic acids in human glioma treatment: innovative approaches and recent results.

Catuogno S, Esposito CL, Quintavalle C, Condorelli G, de Franciscis V, Cerchia L.

J Signal Transduct. 2012;2012:735135. doi: 10.1155/2012/735135. Epub 2012 May 21.

23.

miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis.

Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V.

Oncogene. 2013 Jan 17;32(3):341-51. doi: 10.1038/onc.2012.51. Epub 2012 Feb 27.

PMID:
22370637
24.

Coupling Aptamers to Short Interfering RNAs as Therapeutics.

Cerchia L, Esposito CL, Camorani S, Catuogno S, Franciscis V.

Pharmaceuticals (Basel). 2011 Oct 27;4(11):1434-1449. Review.

25.

A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.

Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, de Franciscis V, Cerchia L.

PLoS One. 2011;6(9):e24071. doi: 10.1371/journal.pone.0024071. Epub 2011 Sep 6.

26.

Nucleic acid aptamers against protein kinases.

Cerchia L, de Franciscis V.

Curr Med Chem. 2011;18(27):4152-8. Review.

PMID:
21838690
27.

New insight into clinical development of nucleic acid aptamers.

Esposito CL, Catuogno S, de Franciscis V, Cerchia L.

Discov Med. 2011 Jun;11(61):487-96. Review.

28.

Recent Advance in Biosensors for microRNAs Detection in Cancer.

Catuogno S, Esposito CL, Quintavalle C, Cerchia L, Condorelli G, De Franciscis V.

Cancers (Basel). 2011 Apr 8;3(2):1877-98. doi: 10.3390/cancers3021877.

29.

Targeting cancer cells with nucleic acid aptamers.

Cerchia L, de Franciscis V.

Trends Biotechnol. 2010 Oct;28(10):517-25. doi: 10.1016/j.tibtech.2010.07.005. Epub 2010 Aug 17. Review.

PMID:
20719399
30.

Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.

Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, de Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, de Franciscis V.

Oncology. 2009;77(6):378-84. doi: 10.1159/000276765. Epub 2010 Jan 18.

PMID:
20090381
31.

Differential SELEX in human glioma cell lines.

Cerchia L, Esposito CL, Jacobs AH, Tavitian B, de Franciscis V.

PLoS One. 2009 Nov 24;4(11):e7971. doi: 10.1371/journal.pone.0007971.

32.

Aptamers as innovative diagnostic and therapeutic agents in the central nervous system.

de Franciscis V, Esposito CL, Catuogno S, Cellai L, Cerchia L.

CNS Neurol Disord Drug Targets. 2009 Nov;8(5):393-401. Review.

PMID:
19702567
33.

GDNF selectively induces microglial activation and neuronal survival in CA1/CA3 hippocampal regions exposed to NMDA insult through Ret/ERK signalling.

Boscia F, Esposito CL, Di Crisci A, de Franciscis V, Annunziato L, Cerchia L.

PLoS One. 2009 Aug 3;4(8):e6486. doi: 10.1371/journal.pone.0006486.

34.

Cell-specific aptamers for targeted therapies.

Cerchia L, Giangrande PH, McNamara JO, de Franciscis V.

Methods Mol Biol. 2009;535:59-78. doi: 10.1007/978-1-59745-557-2_5. Review.

35.

Distribution and bioactivity of the Ret-specific D4 aptamer in three-dimensional collagen gel cultures.

Vento MT, Iuorio M, Netti PA, Ducongè F, Tavitian B, Franciscis V, Cerchia L.

Mol Cancer Ther. 2008 Oct;7(10):3381-8. doi: 10.1158/1535-7163.MCT-08-0580.

36.

A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation.

Esposito CL, D'Alessio A, de Franciscis V, Cerchia L.

PLoS One. 2008 Feb 20;3(2):e1643. doi: 10.1371/journal.pone.0001643.

37.

Shp2 in PC12 cells: NGF versus EGF signalling.

D'Alessio A, Cerchia L, Amelio I, Incoronato M, Condorelli G, de Franciscis V.

Cell Signal. 2007 Jun;19(6):1193-200. Epub 2007 Jan 10.

PMID:
17287109
38.

Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases.

Cerchia L, de Franciscis V.

Methods Mol Biol. 2007;361:187-200. Review.

PMID:
17172712
39.

Comparison of different strategies to select aptamers against a transmembrane protein target.

Pestourie C, Cerchia L, Gombert K, Aissouni Y, Boulay J, De Franciscis V, Libri D, Tavitian B, Ducongé F.

Oligonucleotides. 2006 Winter;16(4):323-35.

PMID:
17155908
40.

Noncoding RNAs in cancer medicine.

Cerchia L, De Franciscis V.

J Biomed Biotechnol. 2006;2006(4):73104.

41.

An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation.

Cerchia L, D'Alessio A, Amabile G, Duconge F, Pestourie C, Tavitian B, Libri D, de Franciscis V.

Mol Cancer Res. 2006 Jul;4(7):481-8.

42.
43.

Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.

Cerchia L, Ducongé F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D.

PLoS Biol. 2005 Apr;3(4):e123. Epub 2005 Mar 22. Retraction in: PLoS Biol. 2015 Jul;13(7):e1002215.

44.

Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex.

Amoresano A, Incoronato M, Monti G, Pucci P, de Franciscis V, Cerchia L.

Cell Signal. 2005 Jun;17(6):717-27. Epub 2004 Nov 13.

PMID:
15722196
45.

The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes.

Incoronato M, D'Alessio A, Paladino S, Zurzolo C, Carlomagno MS, Cerchia L, de Franciscis V.

Cell Signal. 2004 Jul;16(7):847-56.

PMID:
15115663
46.

The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.

D'Alessio A, Califano D, Incoronato M, Santelli G, Florio T, Schettini G, Carlomagno MS, Cerchia L, de Franciscis V.

Endocrinology. 2003 Oct;144(10):4298-305. Epub 2003 Jun 19.

PMID:
12959980
47.

The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret.

Cerchia L, Libri D, Carlomagno MS, de Franciscis V.

Biochem J. 2003 Jun 15;372(Pt 3):897-903.

48.

Nucleic acid aptamers in cancer medicine.

Cerchia L, Hamm J, Libri D, Tavitian B, de Franciscis V.

FEBS Lett. 2002 Sep 25;528(1-3):12-6. Review.

50.

Supplemental Content

Loading ...
Support Center